02. Mai 2018 Evotec expands CRISPR - based technology offering with licence fromers genomics Genomics

Licence provides evotec’s partners with unique integrated solution to identify novel disease-modifying genes; builds upon existing expertise on phenotypic screening, ipsc and disease biology Hamburg, Germany, 02 May 2018:
Evotec AG today announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene editing, thereby complementing and expanding its existing service offering in the CRISPR gene editing space. The new licence from ERS Genomics Limited complements and expands Evotec’s existing CRISPR licences through the Broad Institute with gene editing technology from Emmanuelle Charpentier and others. Dr Mario Polywka, Chief Operating Officer of Evotec, commented:
“Obtaining this new licence from ERS Genomics is the latest example of Evotec’s investment in gene editing technologies. Together with our world-leading iPSC and phenotypic screening platforms, the continued expansion of CRISPR-based technologies at Evotec provides our partners with a unique solution for the identification of novel disease modifying genes.”
Eric Rhodes, CEO of ERS, commented:
“We’re thrilled to add Evotec to our growing list of licensees of CRISPR-Cas9 technology. As one of the world’s leading providers of customised research solutions it’s very gratifying to see Evotec actively expanding its use of the technology across several key areas.” About Evotec’s CRISPR offering
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a naturally occurring bacterial immune system. Researchers have harnessed this system as a genome editing tool for mammalian cells.Evotec has multiple licences to this NEWS RELEASE technology through ERS Genomics and the Broad Institute for the use of the CRISPR-Cas9 gene editing technology.Evotec uses the CRISPR technology to drive its target identification platform as well as aid the deconvolution of targets from phenotypic screening .With the integration of genome-wide arrayed CRISPR libraries into Evotec’s screening platforms, Evotec is harnessing the power of gene deletion and human, cell - based disease models to identify novel targets for downstream drug discovery programmes. Source: Evotec AG Press Release from 02 May 2018: https://www.evotec.com/en/invest/news--announcements/press-releases/p/evotec-expands-crispr-based-technology-offering-with-licence-from-ers-genomics-5674